Clinical trials: Hormone Refractory
Prostatic Neoplasms
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with…
- Trial name
- NCT01618370
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- 215 sites in Belgium, Canada and 17 more
- Volunteers
- 705 people
- Sponsor
- Bayer
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory).
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT04719273
- Testing
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Thomas Jefferson University
Hormone Refractory Prostate Cancer
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients
We propose in this study to treat hormone refractory prostate cancer (HRPC) patients., with a novel preparation of fermented wheat germ nutriment (FWGE), in combination with the 1st line hormone therapy, the gonadotropin…
- Trial name
- NCT00411853
- Testing
- Fermented Wheat germ extract
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Prostate Cancer
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment.
- Trial name
- NCT00183937
- Testing
- PS 341, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Prostatic Neoplasms, Prostate Cancer
Fulvestrant in Hormone Refractory Prostate Cancer
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have…
- Trial name
- NCT00476645
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Hormone Refractory Prostate Cancer
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
This is a parallel, two-arm, open-label, multicenter phase IA/IB study of LBH589 (oral formulation) alone and in combination with docetaxel in patients with progressing hormone refractory prostate cancer.
- Trial name
- NCT00493766
- Testing
- LBH589
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
This randomized phase II trial is studying ixabepilone to see how well it works compared to mitoxantrone and prednisone in treating patients with metastatic prostate cancer that has not responded to paclitaxel, docetaxel, or…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00058084
- Testing
- ixabepilone, mitoxantrone hydrochloride, prednisone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Prostatic Neoplasms
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.
- Trial name
- NCT00448409
- Testing
- TroVax, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- The Methodist Hospital Research Institute
Primary Disease, Prostate Cancer
Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer
The purpose of the trial is to determine the most effective dose of BAy 46-9003 associated to taxotere for first-line treatment of patient with prostatic cancer.
- Trial name
- NCT00405210
- Testing
- sorafenib (200 or 400mg bid) and taxotere iv
- Where
- 6 sites in Belgium, France
- Volunteers
- 38 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Prostate Cancer
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00786682
- Testing
- docetaxel, hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either…
- Trial name
- MEVPRO-1 (NCT06551324)
- Testing
- PF-06821497, Docetaxel, Enzalutamide
- Where
- 224 sites in United States, Argentina and 21 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
Hormone Refractory Prostate Cancer, Prostate Cancer
Study Evaluating the Safety and Tolerability of L-377202
The primary purpose of this study is to (1) determine the maximally tolerated dose (MTD) of L-377202 administered once every 3 weeks, (2) evaluate the safety and tolerability of L-377202 including the dose-limiting adverse…
- Trial name
- NCT00987753
- Testing
- L-377202
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Alabama at Birmingham
Prostate Cancer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT00887198
- Testing
- Abiraterone acetate, Prednisone
- Where
- 134 sites in United States, Australia and 9 more
- Volunteers
- 1,088 people
- Sponsor
- Janssen Research & Development, LLC
Hormone Refractory Prostate Cancer
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer
This study proposed the comparison the overall survival, hematological toxicity, pain reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from different parts of India.
- Trial name
- HRPC (NCT00525408)
- Testing
- Mycobacterium w., Docetaxel
- Where
- 14 sites in India
- Volunteers
- 134 people
- Sponsor
- Cadila Pharnmaceuticals
Prostate Cancer
Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer
The primary objective of the study is to determine a recommended phase II dose (RP2D). The secondary objective of the study are: 1.
- Trial name
- Tax-Sam (NCT00559429)
- Testing
- Docetaxel
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Neoplasm
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide in patients with hormone-refractory prostate cancer.
- Trial name
- NCT00001446
- Testing
- thalidomide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00020254
- Testing
- aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Primary Objective: To assess the tolerability at global doses Secondary Objectives: Safety Pharmacokinetics Efficacy
- Trial name
- NCT01324583
- Testing
- Cabazitaxel (XRP6258), prednisolone
- Where
- 21 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Sanofi